anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A processor of a system trains one or more neural networks to predict a treatment for a patient based, at least in part, on medical imaging data and clinical metadata, and determines a treatment for the patient using the trained neural net. Whether the patient is part of a patient population to receive a treatment is determined. The medical imaging data may comprise slices of a computer tomography scan. The clinical metadata may comprise laboratory measurements of lactate dehydrogenase levels and C-reactive protein levels. The treatment may be for COVID-19. An aggregate image-based treatment probability for a plurality of images may be determined. The aggregate probability and clinical metadata may be normalised to obtain input features used to train a portion of the neural networks to obtain weights indicating how impactful each feature is to determining the treatment. A multi-modal deep learning framework and the EfficientNet convolutional neural network may be used.
Subjects will undergo testing in 2 study phases separated by at least 2 weeks: 1) active phase: subjects will have post meal glucose levels measured across 3 days of participating in their normal exercise routines. Blood vessel health will also be measured via flow mediated dilation at the end of the 3 day monitoring period. 2) physically inactive phase: subjects will stop participating in exercise for 3 days while post meal glucose levels are measured. Blood vessel health will also be assessed on days 1, 3 of removal of exercise. The subject will need to come into the lab on these days of inactivity to have blood vessel health measured.

The study procedures are described below.

Continuous Glucose Monitoring The investigators would like to gain more information about how blood sugar levels change over the course of a day in a free living setting. To do this the investigators will use a continuous glucose monitoring system (CGMS). This system is what individuals with diabetes frequently use to monitor their glucose levels over the course of the day. Subjects will be asked to wear the CGMS for 3 consecutive, full days on 2 different occasions. This includes 3 days during their normal regular physical activity, then for 3 days following during the no exercise protocol. The CGMS is worn on the stomach, and it is a tiny glucose sensor which is inserted just under the skin. This device measures and records blood glucose values throughout the day. In addition, subjects will be asked to make at least four finger stick blood glucose readings taken with a standard glucose meter at different times each day and record these numbers on a log sheet. During the continuous glucose monitoring, subjects will need to consume the same type and quantity of foods at the same time each day (i.e. whatever the subjects consumes on day 1 of baseline testing, they need to eat that exact same food, volume of food and at the same time on days 1-3 of the study). Meals and snacks consumed are also entered into a paper-based diary.

Blood Vessel Health Measurement (Flow Mediated Dilation: FMD) Subjects will be asked to perform their normal exercise routines 12-16 hours prior to blood vessel health being measured in the active phase as well as prior to the first blood vessel health measurement in the inactive phase to control for the acute effects of exercise on blood vessel health. Blood vessel health will be measured at the end of the active phase in both groups of subjects. Further blood vessel health will be measured following 1, 3 days of being inactive in both groups of subjects. Blood flow to the leg will be measured by applying blood pressure cuffs around the ankle. Pre flow mediated dilation diameter and velocity are recorded for 3 minutes prior to a blood pressure cuff being inflated for 5 minutes. Following cuff deflation, a 2-minute diameter and velocity recording is collected.
A molecule imaging diagnosis method is provided to produce expression images of disease-related genes at an expression spot using trans-splicing ribozyme, thereby diagnosing diseases in an early stage. A molecule imaging composition contains a trans-splicing ribozyme vector. The ribozyme vector represents adenovirus vector. A molecule imaging diagnosis method comprises the following steps of: cloning an image reporter gene and ribozyme which targets a specific gene; injecting the cloned ribozyme to a vector to be expressed; and isolating vector confirmed whether the ribozyme is expressed. The ribozyme is connected to a luciferase(luc) gene. The ribozyme targets CKAP2(cytoskeleton-associated protein 2).
All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
A video decoder system collates program guide information acquired from a variety of local and remote sources (405, 415, 420). Program guide information is received from a first source and a selectable program guide menu icon is displayed. A category of program guide information items from the first source is collated (425) by a display attribute in response to selection of the menu icon and the collated program guide information items are displayed (430, 435). The display attribute allocated to the category of program guide information items is common to both the category of items and to the menu icon. Codes identifying program categories may be converted to other codes using equivalence mapping information for classifying programs according to a master set of program categories (425). Composite program map information may be formed including new data identifiers allocated to program guide information items for use in retrieving the items from a second source (420).
A server has a communicator, a decision unit, and a communication control unit. In a case in which a first condition and a second condition are satisfied, the decision unit decides to cause a first client to stop data transmission. In a case in which the first condition and a third condition are satisfied, the decision unit decides to cause a second client to stand by for the data transmission. The first condition indicates that an access point to which the first client is being connected is the same as an access point to which the second client is being connected. The second condition indicates that a priority of the first client is lower than a priority of the second client. The third condition indicates that priority information has not been received from the second client.
Ribozymes are provided in which the ribozymes have a catalytic sequence, two legs and at least one anchor sequence complementary to the substrate mRNA at a location that can be noncontiguous with the portions of the substrate mRNA complementary to the legs. In certain preferred embodiments, ribozymes capable of cleaving the L6 mRNA or both the L6 and K28 mRNAs are provided. Methods are provided for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) patients having the L6 and K28 translocations and, therefore, the L6 mRNA. Additionally, combination treatments comprising components specific for both the K28 and L6 mRNAs are provided. Combination treatments are also provided for those patients which express c-myc in combination with K28 and/or L6 mRNAs. Methods of treatment include, for example, administration of ribozymes and antisense oligonucleotides directed against these mRNAs.
Type II diabetes mellitus (T2DM) is a rising global health burden due to its rapidly increasing prevalence worldwide, and can result in serious complications. Therefore, it is of utmost importance to identify individuals at risk as early as possible to avoid long-term T2DM complications. In this study, we developed an interpretable machine learning model leveraging baseline levels of biomarkers of oxidative stress (OS), inflammation, and mitochondrial dysfunction (MD) for identifying individuals at risk of developing T2DM. In particular, Isolation Forest (iForest) was applied as an anomaly detection algorithm to address class imbalance. iForest was trained on the control group data to detect cases of high risk for T2DM development as outliers. Two iForest models were trained and evaluated through ten-fold cross-validation, the first on traditional biomarkers (BMI, blood glucose levels (BGL) and triglycerides) alone and the second including the additional aforementioned biomarkers. The second model outperformed the first across all evaluation metrics, particularly for F1 score and recall, which were increased from 0.61 ± 0.05 to 0.81 ± 0.05 and 0.57 ± 0.06 to 0.81 ± 0.08, respectively. The feature importance scores identified a novel combination of biomarkers, including interleukin-10 (IL-10), 8-isoprostane, humanin (HN), and oxidized glutathione (GSSG), which were revealed to be more influential than the traditional biomarkers in the outcome prediction. These results reveal a promising method for simultaneously predicting and understanding the risk of T2DM development and suggest possible pharmacological intervention to address inflammation and OS early in disease progression.
Calprotectin (CP) is an inflammatory marker. The aim of the current study was to investigate oxidative stress and changes in CP in cattle with traumatic reticuloperitonitis (TRP). The study was divided into two groups, experimental (TRP) and healthy control group, with 10 animals in each group. Total leucocyte count, neutrophil and lymphocyte counts were higher in the TRP group compared to the control group and this increase was statistically significant (P < 0.001). The level of malondialdehyde (MDA) in TRP group was statistically significantly higher than the control group (P < 0.001). The level of glutathione (GSH) in the TRP group was statistically significantly lower than in the control group (P < 0.001). Serum Amyloid A (SAA) and CP values were higher in the TRP group and this difference was statistically significant (P < 0.001). It was concluded as a result of ROC analysis that CP, which has similar values with SAA, can be used diagnostically to confirm the inflammatory status in cattle with TRP.
BACKGROUND: A coronary artery aneurysm (CAA) is an abnormal dilation of a coronary artery segment often accompanied by coronary artery fistula (CAF), leading to communication between a coronary artery and a cardiac chamber or a part of the coronary venous system. Both CAAs and CAFs can present with symptoms and signs of myocardial ischemia and infarction.
CASE PRESENTATION: We describe the case of a 46-year-old woman with non-ST-elevation myocardial infarction (NSTEMI) caused by a "giant" CAA. Various imaging modalities revealed a thrombus-containing aneurysm located at the right-posterior cardiac border, with established arteriovenous communication with the distal part of left circumflex artery (LCx). After initial treatment with dual antiplatelet therapy, a relapse of pain was reported along with a new increase in troponin levels, electrocardiographic abnormalities, reduced left ventricular ejection fraction (LVEF) and thrombus enlargement. Surgical excision of the aneurysm was favored, revealing its true size of 6 cm in diameter. Τhe aneurysm was excised without complications. The patient remained asymptomatic during follow-up.
CONCLUSIONS: Management of rare entities such as "giant" CAAs and CAFs can be challenging. Cases such as this can serve as precedents to facilitate treatment plans and develop consistent recommendations, emphasizing the importance of personalized strategies for future patients.
The invention relates to the food industry, and more particularly to dietary supplements based on rare-earth metals conducive to maintaining the body in a healthy condition. The present dietary supplement contains the rare-earth metals europium, terbium, lutetium, erbium and thulium. The dietary supplement additionally contains aminoacetic acid (glycine), and succinic acid. The metals europium, terbium, lutetium and erbium are present in the supplement in the form of chlorides, and thulium is present in the form of a nitrate. All of the ingredients are used in specific proportions. Also claimed is a method for the use of the aforementioned dietary supplement, in which the dietary supplement compound is administered orally in daily single doses of from 25 to 125 µg/kg. The invention makes it possible to produce a supplement that exhibits a cardioprotective and anticancer effect.
The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
FIELD: medicine. SUBSTANCE: remedy has polar lipid composition on nicotine basis taken as liquid crystals and their colloid dispersions and in their predecessors or secondary products transformable into liquid crystals or liquid crystal mixtures. The composition operates as matrix of controllable nicotine release useable for giving up smoking and/or substituting smoking. The like compositions of liquid crystals or their dispersions or their predecessors or secondary products containing nicotine and anti- irritants or local analgesic or any their combinations alleviate irritating nicotine action or mask its taste. Available application paths involve buccal introduction like chewing gum produced from liquid crystals, or their dispersions or their predecessors or secondary products or buccal adhesives, gels and covers with liquid crystals, or their dispersions, or their predecessors, or secondary products and aerosol usable in peroral applications with dispersions of liquid crystals and their dispersions or their predecessors or secondary products, nasal aerosol and gel with the said liquid crystals, or their dispersions, or their predecessors or secondary products, local applications as adhesives, gels and covers with the said liquid crystals, or their predecessors, or secondary products being used. EFFECT: avoided adverse side effects; bioavalability; easiness in operation. 34 cl, 6 dwg, 5 tbl
Carpal tunnel release (CTR) is the most performed surgery of the upper extremity. It is effective but not without complications. This state-of-the-art review covers most common intra- and postoperative complications after CTR. As endoscopic carpal tunnel release (ECTR) has developed over time, severe complications, such as nerve lesions, have diminished. ECTR still has a higher risk on transient nerve lesions. Open CTR on the other hand has a higher incidence of wound-related problems, including scar tenderness, irrespective of incision used. Most complications, such as pillar pain and infection, are ill-defined in the literature, leaving the exact incidence unknown and proposing challenges in treatment. The same is true for failure of treatment. Optimizing the length and location of incisions has played a vital role in reducing intra- and postoperative complications in CTR. It is expected that technical advances, such as ultrasound-guided percutaneous carpal tunnel release, will continue to play a role in the future.Level of evidence: V.
Fatty liver disease (FLD) affects approximately 25% of global adult population. Metabolic-associated fatty liver disease (MAFLD) is a term used to emphasize components of metabolic syndrome in FLD. MAFLD does not exclude coexistence of other liver disease, but impact of coexisting MAFLD is unclear. We investigated prevalence and characteristics of MAFLD in patients with biopsy-proven autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), or toxic liver disease. Liver histopathology and clinical data from Helsinki University Hospital district (1.7 million inhabitants) between 2009 and 2019 were collected from patients with AIH, PBC, PSC, or toxic liver disease at the time of diagnosis. MAFLD was diagnosed as macrovesicular steatosis ≥5% together with obesity, type-2 diabetes, or signs of metabolic dysregulation. Of 648 patients included, steatosis was observed in 15.6% (n = 101), of which 94.1% (n = 95) was due to MAFLD. Prevalence of coexisting MAFLD in the four liver diseases varied between 12.4 and 18.2% (P = 0.483). Fibrosis was more severe in MAFLD among patients with toxic liver disease (P = 0.01). Histopathological characteristics otherwise showed similar distribution among MAFLD and non-FLD controls. Alcohol consumption was higher in MAFLD group among patients with AIH or PBC (P < 0.05 for both). In AIH, smoking was more common in patients with coexisting MAFLD (P = 0.034). Prevalence of coexisting MAFLD in other primary liver diseases is lower than reported in general population. Histopathology of MAFLD patients did not clearly differ from non-FLD ones. Alcohol and smoking were associated with MAFLD in AIH.
Patients with chronic pain requiring daily opioid use for pain control turn to invasive surgeries for long-term management of their pain, though there is still a chance of requiring opioid pain medications as well as increased use during the immediate post-operative phase. Ketamine infusion peri-operatively has been shown to decrease post-operative pain from invasive surgeries, such as cervical and lumbar fusions, and there is also evidence that ketamine infusions in general can help to improve levels of chronic pain with less need for opioid medications. Our study asks if pre-operative ketamine infusion will decrease overall pain levels following cervical or lumbar surgery through the post-operative phase, decreasing reliance on opioids for daily pain control, as well as improving mood, functionality, and quality of life for patients that live with chronic pain syndromes. Ketamine, an N-methyl-D-aspartate receptor antagonist, has newly received attention for its ability to provide anesthesia in patients with chronic pain syndromes and neuropathic pain syndromes. Recent studies have shown evidence that intra-operative delivery of ketamine can reduce acute post-operative analgesic consumption in patients following a variety of surgical procedures, though this is often focused on the acute post-operative period (initial 72 hours). Additionally, studies have shown that ketamine infusions in patients with chronic pain requiring opioid analgesics does provide some variable level of baseline pain improvement. For patients with chronic neck or back pain, choosing to undergo invasive spinal surgeries potentially could provide some relief of their daily pain, though there is a chance that they will still require daily narcotics for pain relief post-operatively.
BACKGROUND: With the rising popularity of the deep inferior epigastric perforator (DIEP) flap in breast reconstruction, use of the superficial inferior epigastric vein (SIEV) to augment venous outflow has been proposed as a strategy to prevent venous congestion, a complication positively associated with flap volume. This study evaluated the impact of routine SIEV venous augmentation on the risk of vascular complications or operative fat necrosis in the context of flap size and operating time.
METHODS: A retrospective cohort study compared complication rates of patients with SIEV-augmented DIEP flaps to controls over a 3-year period. Outcomes assessed included vascular complications, defined as venous congestion or compromise requiring take-back, partial flap necrosis, total flap loss, as well as operative fat necrosis. Relative risk was modeled by Cox proportional hazard regression analysis. Sensitivity analysis was performed to assess for an interaction effect by flap mass.
RESULTS: The study sample included 197 patients with 316 flaps. The mean mass of the SIEV-augmented flaps was significantly greater than in the control group (832.9 vs. 653.9 g; p = 0.0007). After adjustment for flap characteristics, patient demographic factors, and comorbidities, pooled risk of vascular complication and operative fat necrosis was found to be significantly lower in the SIEV-augmented group compared to controls (hazard ratio = 0.33, 95% CI [0.11-1.00]; p = 0.0489). Sensitivity analysis demonstrated no effect interaction by flap weight (p = 0.5139).
CONCLUSION: Routine venous outflow augmentation via anastomosis of SIEV to the internal mammary vein perforator at the second intercostal space significantly reduced the risk of vascular complications and operative fat necrosis, regardless of flap weight. No significant increase in operative time was observed among cases in which augmentation was performed.
STUDY OBJECTIVE: Cesarean scar pregnancy (CSP) is a type of ectopic pregnancy associated with severe complications, including significant hemorrhage, the potential need for hysterectomy, and life-threatening risks. Currently, two classification methods exist for CSP: Vial (type Ia and IIa) and Chinese Expert's Consensus (type Ib, type IIb, and type IIIb). However, these methods have limitations in guiding the selection of appropriate treatment plans for CSP. The purpose of this study was to systematically evaluate the effectiveness of various treatments for CSP within our clinic.
METHOD: Our study included 906 patients with CSP from January 2013 to December 2018. The chi-squared test and logistic analysis were used to compare the clinical characteristics. The median and interquartile range (IQR) was calculated. We also analyzed whether preoperative application of methotrexate (MTX) could improve surgical outcomes and the relevant characteristics of misdiagnosed CSP patients.
RESULTS: There was a significant difference in gestational age, gestational sac diameter, gestational sac width, gestational sac area, remnant myometrial thickness, vaginal bleeding and preoperative hemoglobin levels (p < 0.001) but not in the incidence of residual tissue (p = 0.053). The other factors (intraoperative blood loss, hemoglobin decline, first hemoglobin after operation, total hospital stay, hospital stay after operation, transfusion and duration of catheter drain) were significantly different (p < 0.001). For type Ia and type Ib CSP, 39.3% and 40.2% of patients were treated with dilatation and curettage (D&E) under ultrasound, respectively. For type IIa and type IIIb CSP, 29.9% and 62.7% of patients were treated with laparotomy, respectively. There were no differences in surgical methods, residual tissue and reoperation between the MTX and non-MTX groups (p = 0.20), but liver damage, hospital stay and pain perception were more remarkable in the MTX group. It is noteworthy that 14% of the patients were misdiagnosed with an intrauterine pregnancy. The incidence of misdiagnosis in type IIa CSP patients was higher than that in type Ia CSP patients (p < 0.001).
CONCLUSION: For type I CSP patients, D&E under ultrasound or D&E under hysteroscopy should be recommended. For type IIIb CSP patients, operative resection should be used. It is currently difficult to choose the appropriate treatment methods for type IIa or type IIb CSP patients.